Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches

Catherine Handy Marshall, Emmanuel S. Antonarakis

Research output: Contribution to journalArticlepeer-review

Abstract

Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Immunotherapy, particularly immune checkpoint blockers, PARP inhibitors, and PSMA-targeted therapies are all increasingly being studied for the treatment of mCRPC although none are currently FDA-approved specifically for prostate cancer. Together these three classes of treatments may drastically change the future landscape of mCRPC. This review will cover what is currently known about the utility of these agents for the treatment of mCRPC, the areas of active research, and how these agents may be useful for patients in the future. It will also emphasize the notion of biomarker selection to help inform which patients are more likely to respond to these therapies.

Original languageEnglish (US)
Article number100164
JournalCancer Treatment and Research Communications
Volume23
DOIs
StatePublished - 2020
Externally publishedYes

Bibliographical note

Funding Information:
Disclosures: CHM has received research funding to her institution from the Conquer Cancer Foundation (Bristol Myers Squibb) and travel support from Dava Oncology. She also serves as a paid consultant to McGraw-Hill publishing company. ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck. He has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol-Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Funding: This work was partially supported by National Institute of Health Cancer Center Support Grant P30CA006973.

Publisher Copyright:
© 2020 The Author(s)

Keywords

  • Immune checkpoint blockers
  • Immunotherapy
  • Metastatic castration-resistant prostate cancer
  • PARP inhibitors
  • Prostate cancer
  • PSMA
  • Targeted therapy

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches'. Together they form a unique fingerprint.

Cite this